---
title: "Head and Neck Oncologic Surgery"
order: 4
category: "Otolaryngology"
---

# Head and Neck Oncologic Surgery

## Overview

Head and neck cancer represents approximately 3-5% of all malignancies but carries significant morbidity due to the functional and cosmetic importance of affected structures. Most head and neck squamous cell carcinomas (HNSCC) arise from the mucosal surfaces of the upper aerodigestive tract. Treatment requires multidisciplinary collaboration involving surgical oncology, radiation oncology, medical oncology, reconstructive surgery, and supportive care. Modern management emphasizes organ preservation when possible, functional outcomes, and integration of surgical and nonsurgical modalities.

## Epidemiology and Risk Factors

### Incidence

**United States**: ~65,000 new cases annually
**Global**: ~890,000 new cases annually
**Male predominance**: 3:1 ratio (decreasing with HPV-related cancers)
**Age**: Peak incidence 50-70 years

### Risk Factors

**Tobacco**:
- Strongest risk factor for traditional HNSCC
- Dose-dependent (pack-years)
- All forms: Cigarettes, cigars, pipes, smokeless tobacco
- Synergistic with alcohol (multiplicative effect)

**Alcohol**:
- Independent risk factor
- Synergistic with tobacco
- Mechanism: Local mucosal irritation, acetaldehyde carcinogenesis

**Human Papillomavirus (HPV)**:
- **HPV-16** most common oncogenic subtype
- **Oropharyngeal cancer** especially (70-80% HPV-positive)
- **Demographics**: Younger patients, non-smokers, higher socioeconomic status
- **Prognosis**: Better response to treatment, improved survival vs. HPV-negative

**Other Risk Factors**:
- **Betel nut chewing**: Oral cavity cancer (Asia)
- **Prior radiation**: Second malignancies
- **Immunosuppression**: Transplant recipients, HIV
- **Occupational**: Wood dust (nasopharyngeal), nickel (sinonasal)
- **Genetic syndromes**: Fanconi anemia, dyskeratosis congenita
- **Epstein-Barr Virus (EBV)**: Nasopharyngeal carcinoma

## Anatomy and Staging

### Anatomic Subsites

**Oral Cavity**:
- Lips, oral tongue (anterior 2/3), floor of mouth, buccal mucosa, retromolar trigone, hard palate, alveolar ridges
- **Drainage**: Levels I-III cervical lymph nodes

**Oropharynx**:
- Base of tongue, soft palate, tonsils, pharyngeal walls
- **Drainage**: Levels II-IV (retropharyngeal nodes also)

**Hypopharynx**:
- Pyriform sinuses, postcricoid area, posterior pharyngeal wall
- **Drainage**: Levels II-IV (bilateral drainage common)

**Larynx**:
- **Supraglottis**: Epiglottis, aryepiglottic folds, arytenoids, false vocal cords
- **Glottis**: True vocal cords, anterior commissure
- **Subglottis**: Below vocal cords to cricoid
- **Drainage**: Supraglottis (levels II-IV, bilateral), glottis (minimal lymphatics, late metastasis), subglottis (levels IV, VI)

**Nasopharynx**:
- Posterior to nasal cavity, superior to soft palate
- **Drainage**: Retropharyngeal, level II-V (often bilateral)

### Cervical Lymph Node Levels

**Level IA (Submental)**: Between anterior bellies of digastric, above hyoid
**Level IB (Submandibular)**: Between anterior and posterior digastric bellies
**Level II (Upper jugular)**: Skull base to hyoid bone, around upper internal jugular vein
- **IIA**: Anterior to spinal accessory nerve
- **IIB**: Posterior to spinal accessory nerve
**Level III (Middle jugular)**: Hyoid to cricoid cartilage
**Level IV (Lower jugular)**: Cricoid to clavicle
**Level V (Posterior triangle)**: Posterior border of SCM to trapezius
- **VA**: Above cricoid
- **VB**: Below cricoid
**Level VI (Central compartment)**: Hyoid to sternal notch, between carotid arteries (thyroid, trachea, larynx drainage)
**Level VII (Superior mediastinal)**: Below sternal notch

### TNM Staging (AJCC 8th Edition)

**Major Changes in 8th Edition**:
- **HPV-positive oropharyngeal cancer**: Separate staging (better prognosis)
- **Depth of invasion (DOI)**: Now included in oral cavity T-staging
- **Extranodal extension (ENE)**: Upstages to N3b (worse prognosis)

**General Principles**:
- **T**: Tumor size and local invasion
- **N**: Regional lymph node involvement
- **M**: Distant metastasis
- **Stage grouping**: I-IV (I = early, IV = advanced)

**Example: Oral Cavity T-Staging** (8th edition):
- **T1**: ≤2cm, DOI ≤5mm
- **T2**: ≤2cm with DOI >5mm but ≤10mm, OR >2cm but ≤4cm with DOI ≤10mm
- **T3**: >4cm OR any size with DOI >10mm
- **T4a**: Moderately advanced local disease (cortical bone, maxillary sinus, skin)
- **T4b**: Very advanced (masticator space, pterygoid plates, skull base, carotid artery)

**N-Staging** (HPV-negative):
- **N1**: Single ipsilateral node ≤3cm, no ENE
- **N2a**: Single ipsilateral node >3cm but ≤6cm, no ENE
- **N2b**: Multiple ipsilateral nodes ≤6cm, no ENE
- **N2c**: Bilateral or contralateral nodes ≤6cm, no ENE
- **N3a**: Any node >6cm, no ENE
- **N3b**: Any node with ENE (clinical or pathologic)

## Diagnosis and Evaluation

### Clinical Presentation

**Symptoms**:
- **Oral cavity**: Non-healing ulcer, mass, pain, bleeding, loose teeth
- **Oropharynx**: Sore throat, odynophagia, otalgia (referred), neck mass
- **Larynx**: Hoarseness (>2 weeks warrants laryngoscopy), dyspnea, stridor, hemoptysis
- **Hypopharynx**: Dysphagia, odynophagia, referred otalgia, neck mass (often late presentation)
- **Nasopharynx**: Nasal obstruction, epistaxis, otitis media (eustachian tube obstruction), cranial neuropathies

**Physical Examination**:
- **Oral cavity**: Direct visualization, palpation (assess depth of invasion, fixation)
- **Oropharynx/hypopharynx/larynx**: Fiberoptic laryngoscopy (office-based)
- **Neck**: Palpate for lymphadenopathy (size, number, fixation)
- **Cranial nerves**: Especially V, VII, IX, X, XI, XII (skull base involvement)

### Diagnostic Workup

**Tissue Diagnosis** (Required):
- **Office biopsy**: Small accessible lesions
- **Fine needle aspiration (FNA)**: Neck mass (lymph node)
  - Core needle biopsy if FNA non-diagnostic
  - **HPV/p16 testing**: Oropharyngeal primary (prognostic, staging)
- **Examination under anesthesia (EUA) with biopsy**: Most cases
  - Direct laryngoscopy, esophagoscopy (panendoscopy)
  - Document tumor extent, obtain biopsy
  - **Triple endoscopy**: Look for synchronous primary (lungs, esophagus) - 3-7% incidence

**Imaging**:
- **CT neck with contrast**: Assess primary tumor, nodal disease
  - Bone invasion, cartilage invasion, nodal size, ENE
- **MRI neck**: Better soft tissue resolution, perineural spread, skull base
- **PET/CT**: Detect distant metastasis, occult primary (unknown primary), post-treatment surveillance
  - Recommended for advanced disease (stage III-IV)
- **Chest imaging**: CT chest (rule out lung metastasis, second primary)

**Laboratory**:
- **CBC, CMP**: Baseline, nutritional status
- **HIV, hepatitis**: If risk factors
- **TSH**: If neck radiation planned (thyroid dysfunction common)

**Dental Evaluation**: Before radiation (extract non-restorable teeth, fluoride trays) - prevent osteoradionecrosis

**Speech/Swallow Evaluation**: Baseline function (compare post-treatment)

**Nutritional Assessment**: Weight loss common, may need feeding tube

## Treatment Principles

### Multidisciplinary Approach

**Tumor Board**: Discuss all cases with surgeons, radiation oncologists, medical oncologists, radiologists, pathologists, nutritionists, speech therapists

**Treatment Modalities**:
1. **Surgery**: Primary tumor resection + neck dissection
2. **Radiation therapy (RT)**: Definitive or adjuvant
3. **Chemotherapy**: Concurrent with RT (chemoradiation), induction, palliative
4. **Immunotherapy**: Recurrent/metastatic disease (pembrolizumab, nivolumab - PD-1 inhibitors)

### Treatment Selection

**Early Stage (I-II)**:
- **Single modality**: Surgery OR radiation (similar cure rates)
- Choice based on: Functional outcomes, patient preference, comorbidities

**Advanced Stage (III-IV)**:
- **Combined modality**: Surgery + adjuvant RT (or chemoRT if adverse features), OR definitive chemoRT
- **Organ preservation**: Larynx/hypopharynx cancer - chemoRT preferred if feasible (preserve voice/swallow)
- **Surgery indicated**: Resectable disease with poor RT response expected, salvage after RT failure

**Unresectable or Metastatic**:
- Palliative chemotherapy, immunotherapy, palliative RT

### Adjuvant Therapy Indications

**Postoperative Radiation**:
- T3-T4 primary
- Close margins (<5mm)
- Perineural invasion
- Lymphovascular invasion
- N2-N3 nodal disease
- Level IV-V nodes (oral cavity primary)

**Postoperative Chemoradiation** (radiation + cisplatin):
- **Positive margins**
- **Extranodal extension (ENE)**
- Both high-risk features warrant concurrent chemotherapy

## Surgical Procedures

### Oral Cavity Cancer

**Resection Principles**:
- En bloc resection with 1cm margins (mucosal and deep)
- **Depth of invasion**: Critical prognostic factor
- **Bone invasion**: Marginal mandibulectomy (cortex only) vs. segmental mandibulectomy (full-thickness)

**Tongue Cancer**:
- **Partial glossectomy**: Small lesions (T1-T2)
- **Hemiglossectomy**: Larger lesions, up to midline
- **Subtotal/total glossectomy**: Extensive disease (rare, significant functional impairment)

**Floor of Mouth**:
- Resect involved mucosa, mylohyoid muscle if invaded
- Mandibular involvement: Marginal or segmental mandibulectomy

**Buccal Mucosa**:
- Full-thickness cheek resection if deep invasion
- Often requires skin graft or flap reconstruction

**Reconstruction**: Free flap (radial forearm, anterolateral thigh, fibula) for large defects

### Oropharyngeal Cancer

**Transoral Resection**:
- **Transoral laser microsurgery (TLM)**: CO2 laser, en bloc or piecemeal resection
- **Transoral robotic surgery (TORS)**: Da Vinci robot, improved visualization, access to base of tongue/tonsil
- **Advantages**: Avoid mandibulotomy, faster recovery, less morbidity
- **Indications**: T1-T2 (selected T3), good exposure

**Open Approaches**:
- **Mandibulotomy**: Midline mandible split, swing laterally for access
- **Lateral pharyngotomy**: Transcervical approach
- **Indications**: Poor transoral access, large tumors

**HPV-Positive Oropharyngeal Cancer**:
- Better prognosis, de-intensification trials ongoing
- TORS emerging as primary modality (reduce radiation dose/volume)

### Laryngeal Cancer

**Conservation Laryngeal Surgery** (preserve voice/swallow):
- **Vocal cord stripping**: T1a (limited to mid-cord)
- **Cordectomy**: Endoscopic or open, remove vocal cord
- **Supraglottic laryngectomy**: Remove supraglottis, preserve glottis (voice)
  - **Indications**: T1-T2 supraglottic, no glottic involvement
  - **Function**: Voice preserved, aspiration risk initially
- **Supracricoid laryngectomy**: Remove thyroid cartilage, false cords, variable vocal cord resection
  - Preserve cricoid, arytenoid(s)

**Total Laryngectomy**:
- **Indications**: T3-T4 glottic (cartilage invasion), salvage after RT failure, T4a with massive soft tissue invasion
- **Procedure**: Remove entire larynx (hyoid to trachea), create permanent tracheostoma, separate airway from pharynx
- **Consequences**: Loss of voice (alaryngeal speech options: tracheoesophageal puncture with voice prosthesis, electrolarynx, esophageal speech), loss of smell (no nasal airflow), neck breathing
- **Reconstruction**: Primary pharyngeal closure or flap if large defect

**Organ Preservation**:
- **Chemoradiation** preferred for larynx preservation (if feasible)
- **VA Larynx Trial**: Induction chemo + RT vs. surgery + RT (similar survival, 64% larynx preservation)
- Not appropriate if: Extensive cartilage destruction, airway obstruction requiring tracheostomy, high risk of aspiration

### Hypopharyngeal Cancer

**Challenging**: Late presentation, poor prognosis

**Partial Pharyngectomy**:
- Limited disease, preserve function

**Total Laryngopharyngectomy**:
- Extensive disease
- Remove larynx + hypopharynx
- Reconstruction: Free jejunal flap, radial forearm flap, anterolateral thigh flap

**Chemoradiation**: Often preferred (organ preservation) if resectable

### Neck Dissection

**Purpose**: Remove cervical lymph nodes at risk for metastasis

**Types**:

**1. Selective Neck Dissection**:
- Remove specific levels based on primary site
- **Supraomohyoid**: Levels I-III (oral cavity)
- **Lateral**: Levels II-IV (oropharynx, larynx, hypopharynx)
- **Posterolateral**: Levels II-V (skin malignancies)
- **Central**: Level VI (thyroid, larynx, hypopharynx)

**2. Modified Radical Neck Dissection (MRND)**:
- Levels I-V
- **Preserve**: Sternocleidomastoid (SCM), internal jugular vein (IJV), spinal accessory nerve (CN XI)
- **Types**:
  - Type I: Preserve all three structures
  - Type II: Sacrifice one structure
  - Type III: Sacrifice two structures

**3. Radical Neck Dissection (RND)**:
- Levels I-V
- **Remove**: SCM, IJV, CN XI (in addition to nodes)
- **Indications**: Extensive nodal disease with extracapsular extension, direct involvement of structures
- **Morbidity**: Shoulder dysfunction (CN XI), venous congestion (IJV), cosmetic deformity (SCM)

**4. Extended Neck Dissection**:
- Standard dissection + additional structures (parapharyngeal space, parotid, skin)

**Elective Neck Dissection** (cN0):
- **Indications**: Risk of occult metastasis >15-20%
  - Oral cavity: T2 or greater, DOI >4mm
  - Oropharynx, larynx, hypopharynx: Most T2 or greater
- Removes occult disease, provides staging information

**Therapeutic Neck Dissection** (cN+):
- Clinically or radiographically positive nodes

**Bilateral Neck Dissection**:
- Tumors crossing midline or high risk of contralateral metastasis (base of tongue, soft palate, supraglottic larynx)

### Reconstruction

**Goals**: Restore form and function (speech, swallow, airway, cosmesis)

**Local/Regional Flaps**:
- **Pectoralis major myocutaneous flap**: Reliable, bulky (pharyngeal reconstruction, skull base)
- **Submental flap**: Thin, good for oral cavity

**Free Flaps** (microvascular):
- **Radial forearm free flap (RFFF)**: Thin, pliable (tongue, floor of mouth, pharynx)
- **Anterolateral thigh (ALT)**: Versatile, variable thickness (large defects)
- **Fibula free flap**: Bone reconstruction (mandible)
- **Jejunal free flap**: Circumferential pharyngeal reconstruction

**Selection**: Based on defect size, tissue type needed, patient factors

## Postoperative Management

### Immediate Care

**Airway**:
- Tracheostomy common (laryngeal edema, secretions)
- Monitor for hematoma, airway obstruction

**Drains**:
- Jackson-Pratt or Blake drains in neck (prevent seroma/hematoma)
- Remove when output <30mL/day

**Free Flap Monitoring**:
- Flap checks every 1-2 hours (color, temperature, capillary refill, Doppler signal)
- Early recognition of vascular compromise (24-48 hours most critical)

**Nutrition**:
- NPO initially (allow pharyngeal healing)
- **Feeding tube**: Nasogastric or gastrostomy (placed intraoperatively or preoperatively)
- Advance to oral diet based on swallow function (typically 7-14 days)

### Complications

**Early**:
- **Hematoma**: Return to OR for evacuation (airway risk)
- **Free flap failure**: Vascular thrombosis (1-5%), return to OR for exploration/revision
- **Seroma**: Common, drain management
- **Wound infection**: Antibiotics, local wound care
- **Salivary fistula**: Pharyngeal suture line breakdown, saliva leak
  - Management: NPO, drain, antibiotics, may require surgical repair
- **Chyle leak**: Injury to thoracic duct (left neck, low dissection)
  - Management: Low-fat diet, pressure dressing, octreotide; surgical ligation if high-output

**Late**:
- **Dysphagia**: Common, especially after total laryngectomy, base of tongue resection
  - Speech therapy, dietary modification, may require long-term tube feeding
- **Aspiration**: Laryngeal surgery, cranial nerve injury
- **Shoulder dysfunction**: CN XI injury/sacrifice, radiation fibrosis
  - Physical therapy critical
- **Hypothyroidism**: After neck dissection + radiation (20-50%)
- **Osteoradionecrosis**: Mandible bone necrosis after radiation (especially dental extractions)
  - Prevention: Dental clearance before RT, hyperbaric oxygen if high-risk extractions needed post-RT

### Adjuvant Therapy

**Timing**: Start radiation within 6 weeks of surgery (if delayed, risk of recurrence increases)

**Duration**: 6-7 weeks (standard fractionation)

**Toxicities**: Mucositis, dysphagia, xerostomia (dry mouth from salivary gland damage), dermatitis, lymphedema

## Outcomes and Prognosis

### Survival

**Early Stage (I-II)**: 70-90% 5-year overall survival
**Advanced Stage (III-IV)**: 30-60% 5-year overall survival

**HPV-Positive Oropharyngeal Cancer**: 80-90% 5-year survival (significantly better than HPV-negative)

**Negative Prognostic Factors**:
- Advanced T stage
- Nodal metastasis (especially N2-N3)
- Extranodal extension
- Positive margins
- Perineural invasion
- Lymphovascular invasion

### Functional Outcomes

**Speech**:
- Laryngeal preservation (chemoRT): Generally good
- Total laryngectomy: Alaryngeal speech (voice prosthesis best results, 70-80% successful)

**Swallow**:
- Variable depending on extent of resection, radiation
- 20-40% require long-term tube feeding (advanced larynx/hypopharynx cancer)

**Quality of Life**:
- Significant impact from treatment (xerostomia, dysphagia, pain, cosmesis)
- Support services essential: Speech therapy, nutrition, psychology

### Surveillance

**Schedule**:
- **Year 1**: Every 1-3 months
- **Year 2**: Every 2-4 months
- **Year 3-5**: Every 4-6 months
- **After 5 years**: Annually

**Components**:
- Physical examination (primary site, neck)
- Fiberoptic laryngoscopy
- Imaging: CT/MRI neck for symptoms, annual chest imaging (second primary)
- PET/CT: 3-6 months post-treatment (baseline), then for suspected recurrence

**Recurrence**: 30-40% of advanced stage cancers
- Most within 2 years
- Salvage surgery, reirradiation, or palliative care depending on extent

## Special Topics

### Unknown Primary

**Definition**: Cervical lymph node metastasis with no identifiable primary tumor (3-5% of head and neck cancers)

**Workup**:
- Panendoscopy with directed biopsies (nasopharynx, tonsils, base of tongue, pyriform)
- **Tonsillectomy**: Ipsilateral (oropharyngeal primary common, especially HPV-positive)
- PET/CT
- HPV/p16 testing (if squamous cell carcinoma)

**Treatment**:
- Neck dissection + radiation to potential mucosal sites (nasopharynx, oropharynx, hypopharynx)
- Prognosis similar to known primary if treated appropriately

### Nasopharyngeal Carcinoma

**Unique Features**:
- **EBV-associated** (endemic in Southeast Asia, North Africa)
- **Types**: WHO Type I (keratinizing SCC), Type II (non-keratinizing), Type III (undifferentiated - most common, best prognosis)
- **Presentation**: Nasal obstruction, epistaxis, otitis media, cranial neuropathies (skull base invasion), neck mass

**Treatment**:
- **Chemoradiation** (not surgery - nasopharynx inaccessible, radiosensitive)
- Excellent cure rates for early stage (70-90%)

**Surveillance**: EBV DNA levels (monitor for recurrence)

### Cutaneous Malignancies

**Squamous Cell Carcinoma (SCC)** and **Melanoma** of head/neck skin:
- Parotidectomy if parotid nodal involvement
- Neck dissection: Posterolateral (levels II-V) + parotidectomy

**Merkel Cell Carcinoma**:
- Aggressive neuroendocrine tumor
- Surgery + adjuvant RT, often sentinel node biopsy

### Salivary Gland Malignancies

**Types**: Mucoepidermoid carcinoma (most common), adenoid cystic carcinoma, acinic cell carcinoma, adenocarcinoma
**Treatment**: Surgery (parotidectomy, submandibular gland excision) + adjuvant RT for high-grade, advanced stage, close margins
**Facial Nerve**: Preserve if not directly invaded (parotid tumors)

## Advances and Future Directions

**Immunotherapy**:
- PD-1 inhibitors (pembrolizumab, nivolumab): FDA-approved for recurrent/metastatic HNSCC
- Improved survival vs. chemotherapy in platinum-refractory disease
- Ongoing trials: First-line therapy, combination regimens

**De-intensification**:
- HPV-positive oropharyngeal cancer: Trials reducing RT dose, omitting chemotherapy (reduce toxicity while maintaining cure)

**Transoral Robotic Surgery (TORS)**:
- Expanding indications, improved functional outcomes
- Minimize need for mandibulotomy

**Molecular Profiling**:
- Targeted therapies based on genomic alterations (EGFR, PIK3CA mutations)

**Circulating Tumor DNA (ctDNA)**:
- Surveillance for recurrence, guide treatment decisions

## Key Points

- Head and neck squamous cell carcinoma accounts for 90% of head and neck malignancies, primarily affecting oral cavity, oropharynx, larynx, and hypopharynx
- Major risk factors: tobacco, alcohol (synergistic), HPV (oropharynx, better prognosis)
- Multidisciplinary evaluation essential: surgery, radiation, medical oncology, speech, nutrition
- Early stage (I-II) treated with single modality (surgery OR radiation); advanced stage (III-IV) requires combined modality
- Positive margins and extranodal extension (ENE) mandate postoperative chemoradiation
- Neck dissection types: Selective (specific levels), modified radical (I-V, preserve SCM/IJV/CN XI), radical (I-V, sacrifice structures)
- Elective neck dissection indicated if risk of occult metastasis >15-20% (e.g., T2 oral cavity with DOI >4mm)
- Larynx preservation with chemoradiation preferred when feasible; total laryngectomy for advanced disease or salvage
- Free flap reconstruction critical for large defects: radial forearm (thin), anterolateral thigh (versatile), fibula (mandible)
- HPV-positive oropharyngeal cancer has separate staging (8th AJCC) and better prognosis (80-90% 5-year survival)
- Major complications: salivary fistula, chyle leak, flap failure (1-5%), shoulder dysfunction (CN XI injury), dysphagia
- Adjuvant radiation started within 6 weeks post-surgery; delays increase recurrence risk
- Surveillance intensive first 2 years (most recurrences); PET/CT at 3-6 months post-treatment for baseline
- Immunotherapy (pembrolizumab, nivolumab) approved for recurrent/metastatic disease, improving outcomes
- Unknown primary: Panendoscopy with tonsillectomy, PET/CT; treat with neck dissection + mucosal radiation

## References

1. National Comprehensive Cancer Network (NCCN) Guidelines: Head and Neck Cancers (2024)
2. Pfister DG, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(7):873-898
3. Lydiatt WM, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122-137
4. Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(24):24-35
5. Forastiere AA, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845-852
